DaVita Inc. (DVA) 2024 Annual Report Summary
Business Context and Reporting Period
This summary covers DaVita Inc.'s Form 10-K for the fiscal year ended December 31, 2024. DaVita is a leading healthcare provider focused on kidney care, operating primarily in the United States with significant international presence. The company's core business is U.S. dialysis services, supplemented by U.S. Integrated Kidney Care (IKC), other ancillary services, and international operations. As of December 31, 2024, the company operated 2,657 outpatient dialysis centers in the U.S. serving approximately 200,800 patients, and 509 centers internationally serving approximately 80,300 patients.
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Consolidated Revenues | $12.82 billion | $12.14 billion | +5.6% |
| Operating Income | $2.09 billion | $1.60 billion | +30.4% |
| Adjusted Operating Income | $1.98 billion | $1.64 billion | +21.2% |
| Net Income Attributable to DaVita Inc. | $936 million | $692 million | +35.3% |
| Diluted EPS (Attributable to DaVita Inc.) | $10.73 | $7.42 | +44.6% |
| Operating Cash Flow | $2.02 billion | $2.06 billion | -1.8% |
| Free Cash Flow | $1.16 billion | $1.24 billion | -6.0% |
| Total Debt Principal Outstanding | $9.51 billion | $8.45 billion | +12.5% |
| Cash and Cash Equivalents | $795 million | $380 million | +109.2% |
Material Changes vs. Prior Period
- Revenue Growth: U.S. dialysis revenue grew 4.2% driven by a $13.88 increase in average patient service revenue per treatment. Ancillary services revenue grew 16.2%, primarily due to international operations.
- Profitability: Operating income increased significantly, aided by a $109 million non-cash gain on changes in ownership interests (consolidation of previously non-consolidated partnerships) and lower center closure costs compared to 2023.
- Debt Structure: The company refinanced a portion of its Term Loan B-1, extending maturity to 2031, and issued $1.0 billion of 6.875% Senior Notes due 2032. Debt expense increased 17.8% to $470 million due to higher interest rates and increased debt balances.
- Share Repurchases: The company repurchased 9.83 million shares for $1.39 billion, reducing the outstanding share count by 9.3% year-over-year.
- Operational Headwinds: Treatment volumes were impacted by elevated mortality rates and severe weather events causing missed treatments. A supply chain disruption affecting home dialysis supplies also temporarily paused new starts in that modality.
Guidance, Outlook, and Risks
2025 Outlook: Management expects relatively flat year-over-year treatment volumes due to elevated mortality, missed treatments from severe weather, and lingering supply chain impacts on home dialysis. Operating income growth is expected to be driven by revenue per treatment improvements (rate increases, billing mix) and the incorporation of oral phosphate binder reimbursement, partially offset by increased costs for labor, supplies, and the new drug inclusion.
Key Risks and Contingencies:
- Regulatory & Reimbursement: Significant reliance on government payors (67% of U.S. dialysis revenue). Risks include potential changes to Medicare ESRD bundled payment rates, Medicaid policies, and the expiration of ACA premium tax credits in 2025 which could reduce commercial patient mix.
- Legal Proceedings: The company is subject to various investigations, including a 2017 U.S. Attorney Colorado investigation (settled in May 2024 for $34.5 million) and ongoing inquiries regarding charitable premium assistance and antitrust matters.
- Supply Chain & Cybersecurity: Disruptions from severe weather impacted supplier facilities. A 2024 cybersecurity breach at Change Healthcare (a key billing intermediary) caused temporary delays in claims processing and collections, though operations have resumed.
- Labor Costs: Continued pressure from wage inflation, labor shortages, and union organizing activities (e.g., petitions in California clinics).
Investor Verification Checklist
- Commercial Mix Sensitivity: Verify the percentage of patients with commercial insurance versus government payors, as commercial rates drive the majority of profits.
- Phosphate Binder Impact: Monitor the financial impact of the January 1, 2025 inclusion of oral phosphate binders into the Medicare ESRD bundle and the adequacy of the Transitional Drug Add-on Payment Adjustment (TDAPA).
- Debt Service Capacity: Review the leverage ratio (target 3.0x-3.5x Consolidated EBITDA) and the ability to service increased debt obligations given the higher interest rate environment.
- Legal Settlements: Track the resolution of ongoing legal matters, particularly those related to charitable premium assistance and potential False Claims Act liabilities.
- Supply Chain Resilience: Assess the status of home dialysis supply availability and the recovery of treatment volumes following the 2024 supplier disruption.